Discover KRAZATI® (adagrasib), an oral treatment for adult patients with previously treated KRAS G12C-positive NSCLC or CRC. Learn about safety, testing, and support options.

Find out how KRAZATI® (adagrasib), an oral, FDA approved treatment, works for adult patients with NSCLC and whose tumor has an abnormal KRAS G12C gene.

Q: What is KRAZATI? A: KRAZATI is a prescription medicine used in adults alone to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be …

KRAZATI is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose

Learn about the common driver mutation, significance of biomarker testing, and treatment option with KRAZATI® (adagrasib) for KRAS G12C-positive non-small cell lung cancer (NSCLC).

Learn about taking KRAZATI® (adagrasib) for adult patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Follow recommended dosages and manage side effects.

Learn how KRAZATI® (adagrasib) worked for patients with NSCLC and whose tumor has an abnormal KRAS G12C gene in the clinical trial. See study results.

Access comprehensive support for patients with CRC and whose tumor has an abnormal KRAS G12C gene, including financial assistance and community resources from KRAZATI® …

Learn about taking KRAZATI® (adagrasib), including dosages, administration, and side effects for adult patients with KRAS G12-positive colorectal cancer (CRC).

Learn about taking KRAZATI® (adagrasib), including dosages, administration, and side effects for adult patients with KRAS G12-positive colorectal cancer (CRC).